Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer

Infectious Agents and Cancer

Volumn 9, Issue 1, 2014, Pages

  Sobota, Rafal S ^a,b,f   Ramogola Masire, Doreen ^c,d,e   Williams, Scott M ^b   Zetola, Nicola M ^c,d,e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BOTSWANA UPENN PARTNERSHIP   (Botswana)

^e UNIVERSITY OF BOTSWANA   (Botswana)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Coinfection; HPV; Immune cross protection; Taxonomy; Vaccine

Indexed keywords

CD4 ANTIGEN;

ADULT; AGE; ARTICLE; BOTSWANA; CANCER GRADING; CANCER GROWTH; CD4 LYMPHOCYTE COUNT; COLPOSCOPY; CROSS PROTECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; SEXUAL INTERCOURSE; SEXUALITY; TAXONOMY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 84906924246     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-9-26     Document Type: Article

References (17)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Canc J Int Canc 2010 127 12 2893 2917
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N, J Pathol 1999 189 1 12 19
3. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Cancer Res 2010 70 8 3159 3169
4. Human papillomaviruses: genetic basis of carcinogenicity. Burk RD, Chen Z, Van Doorslaer K, Publ Health Genomics 2009 12 5-6 281 290
5. Classification of papillomaviruses. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H, Virology 2004 324 1 17 27
6. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM, Virology 2010 401 1 70 79
7. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Guindon S, Gascuel O, Syst Biol 2003 52 696 704
8. Evolution of the Papillomaviridae. Doorslaer KV, Virology 2013 445 11 20
9. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Schiffman M, Clifford G, Buonaguro FM, Infect Agents Canc 2009 4 8
10. Chapter 3: HPV type distribution in women with and without cervical neoplastic diseases. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL, Vaccine 2006 24 Suppl 3 26 34
11. Quadrivalent human papillomavirus vaccine. Barr E, Tamms G, Clin Infect Dis: Offic Publ Infect Dis Soc Am 2007 45 5 607 609
12. Risk factors for cervical intraepithelial neoplasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire. Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, Lenaud S, Messou E, Minga A, Sasco AJ, West Africa PLoS One 2014 9 3 90625
13. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Keam SJ, Harper DM, Drugs 2008 68 3 359 372
14. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. Mariani L, Venuti A, J Transl Med 2010 8 105
15. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M, Lancet Infect Dis 2012 12 10 781 789
16. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Siddiqui MA, Perry CM, Drugs 2006 66 9 1263 1271 discussion 1272-1263
17. Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. Camargo M, Soto-De Leon SC, Munoz M, Sanchez R, Peňa-Herrera D, Pineda-Peňa AC, Sussmann O, Paez C, Perez-Prados A, Patarroyo ME, BMC Cancer 2014 14 1 451